Property:Inclusion criteria
This is a property of type Text.
D
Both sexes, age ≥ 18 years; tumors of oropharynx or oral cavity; no prior radiotherapy;
primary or secondary radiotherapy; written informed consent; expected compliance +
E
Ehrenpreis et al. (2005): A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy +
- Completed external beam radiation or seed implantation for a pelvic malignancy, including cancer of the prostate, cervix, or uterus at least six months before enrollment
- At least two symptoms (diarrhea, rectal urgency, rectal pain, tenesmus, rectal bleeding, and fecal incontinence) with a severity score of 3 (moderate problem-cannot be ignored; no effect on daily activities) on at least a weekly basis +
Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy +
Patients receiving standardized abdomen and pelvic irradiation 5000 cGy (1000 cGy weekly) for prostate, uterus, cervix, bladder, rectum and colon +
Ertekin et al. (2004): Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study +
Histologically proven cancer of the head and neck (Karnofsky’s performance status ≥70) who were to receive curative radiotherapy or chemoradiotherapy +
F
Fahimi et al. (2011): Evaluating the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens +
Diagnosis of cancer and receiving cisplatin-based regimens at least for two cycles of the chemotherapy, receiveing one of the standard antiemetic regimens [5-HT3 antagonist (granisetrone) and corticostreoid (hydrocortisone)], being able to swallow capsules +
Fallahi et al. (2013): Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? +
Aged less than 55 years, who were referred to our institute for 131I therapy to ablate the remnant thyroid tissue or to treat metastatic tumor, were enrolled in this study; all patients were in a hypothyroid state with serum thyroid stimulating hormone levels higher than 25 mIU/l +
Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
Advanced incurable stage of cancer; ≥ 18 years of age; clinical diagnosis of cancer-related pain unalleviated by an optimized maintenance dose of Step 3 opioid therapy; ≤ 4 opioid breakthrough analgesic episodes per day (averaged over the 3 days); stable maintenance opioid therapy dose; average pain ≥ 4 and ≤ 8 on a 0–10 NRS; average pain scores on the NRS that did not change by more than 2 points from the beginning to end of screening (i.e. no more than a 2-point difference between the highest and lowest scores, with all scores remaining between 4 and 8 +
Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
Advanced incurable stage of cancer; ≥18years of age; clinical diagnosis of cancer-related pain unalleviated by an optimized maintenance dose of Step 3 opioid therapy; ≤4 opioid breakthrough analgesic episodes per day (averaged over the 3 days); stable maintenance opioid therapy dose; average pain ≥ 4 and ≤8 on a 0–10 NRS; average pain scores on the NRS that did not change by more than 2 points from the beginning to end of screening (i.e. no more than a 2-point difference between the highest and lowest scores, with all scores remaining between 4 and 8 +
Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial +
Patients with a confirmed histologic diagnosis of cancer of the oral cavity and oropharynx referred to Radiotherapy; Admission requirements consisted of: (1) a minimal irradiated buccal mucosal area 12.2 cm2 or greater; the limits of this area, measured on verification films, were the hard palate (superior), the floor of the mouth (inferior), the anterior border of the vertical portion of the mandible (posterior), and the distal border of the irradiation field (anterior); (2) age at least 21 years; (3) Zubrod performance status grade 2 or lower; (4) tolerance of solid food at study entry +
Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial +
≥18 years old, had advanced and/or metastatic cancer in palliative phase (any type of cancer), a life expectancy of at least three months as assessed by one of the three study physician and 25-OHD ≤50 nmol/L +
Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) +
Primary treatment for prostate cancer (radical prostatectomy or definitive local radiation including external beam radiation, brachytherapy or both); prostate specific antigen (PSA) within the past two months of between 3 and 20ng/ml if prior local radiation or between 0.4 and 20 ng/ml if prior radical prostatectomy; prostate specific antigen doubling time (PSADT) >3 and <36 months; BMI ≥24 kg/m2 +
G
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
NI +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
Underwent a transurethral resection (TUR) for a histologically confirmed low-grade or high-grade non-invasive urothelial carcinoma (transitional cell carcinoma of the bladder), stage Ta, T1, or carcinoma in situ (Tis) +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
NI +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Aged ≥18 years; any malignancy of any stage; receiving intravenous
chemotherapy of moderate or high emetogenic risk; receive at least two more consecutive cycles; refractory CINV (defined as emesis, and/or nausea of moderate severity on a 5-point rating scale, and/or requiring use of rescue medications) in earlier chemotherapy cycles despite guideline-consistent antiemetic prophylaxis consisting of corticosteroids, a 5-HT3 antagonist,
and an NK-1 antagonist with or without olanzapine where indicated +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
Biopsy-proven squamous cell carcinoma of the head and neck: oral cavity or oropharynx staged T1-T3 at subsites, alveolo-buccal, oral tongue, base of tongue, epiglottis/vallecula, tonsil and pharyngeal wall (lateral or posterior); previous chemotherapy was allowed +
H
Hajimohammadebrahim-Ketabforoush et al. (2019): Effect of Vitamin D Supplementation on Postcraniotomy Pain After Brain Tumor Surgery: A Randomized Clinical Trial +
At least 18 years of age with newly diagnosed brain tumor with serum level of 25 (OH) vitamin D ≤20 ng/dL +
Halyard et al. (2007): Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4) +
Head and neck cancer patients scheduled to receive ≥2,000 cGy of external beam radiotherapy to ≥30% of the oral cavity; ≥18 years of age; life expectancy of ≥3 months (as determined by the physician’s judgment); Eastern Cooperative performance score of 0, 1, or 2; be able to take oral medications reliably and be alert and competent;
receiving amifostine and/or concomitant chemotherapy was allowed +
Heggie et al. (2002): A phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue +
Women >18 years; indication for radiotherapy for breast cancer after lumpectomy or partial mastectomy; chemotherapy as part of the treatment regimen was acceptable +
Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer +
Patients referred to local curative radiotherapy with external beam radiotherapy (EBRT), in combination with hormone ablation; Adenocarcinoma of the prostate must be histologically confirmed on biopsy; life expectancy greater than 5 years; no metastatic disease detected during physical examination, standard radiography, bone scan, and magnetic resonance spectroscopy (MRS); no prior hormone therapy, radiotherapy or systemic treatment for prostate cancer and no other malignancy +